Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Iron Triangle Partners LP

Iron Triangle Partners LP cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 492,471 shares of the company's stock after selling 17,529 shares during the period. Twist Bioscience comprises about 2.5% of Iron Triangle Partners LP's portfolio, making the stock its 16th biggest position. Iron Triangle Partners LP owned about 0.83% of Twist Bioscience worth $22,885,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in TWST. Arizona State Retirement System grew its stake in shares of Twist Bioscience by 1.3% during the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after purchasing an additional 219 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. Hillsdale Investment Management Inc. grew its stake in shares of Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after purchasing an additional 300 shares during the last quarter. Deerfield Management Company L.P. Series C raised its position in Twist Bioscience by 1.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock worth $1,107,000 after buying an additional 403 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after purchasing an additional 443 shares during the period.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the transaction, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 1,101 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $41,452.65. Following the sale, the senior vice president now owns 129,380 shares of the company's stock, valued at $4,871,157. This represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,991 shares of company stock valued at $742,654. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Trading Up 2.8%

TWST traded up $0.83 during trading on Friday, hitting $30.93. 1,288,952 shares of the company's stock were exchanged, compared to its average volume of 969,540. Twist Bioscience Co. has a 1 year low of $28.46 and a 1 year high of $60.90. The stock has a 50 day moving average price of $37.98 and a 200 day moving average price of $43.37. The firm has a market cap of $1.85 billion, a P/E ratio of -9.15 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. As a group, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TWST. Robert W. Baird lowered their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. The Goldman Sachs Group lowered their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.